Evaluating Glofitamab with Salvage Therapy for B-cell Non-Hodgkin Lymphoma in Adults
A Prospective, Observational Study to Explore the Efficacy and Safety of Salvage Therapy With Glofitamab in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
The First Affiliated Hospital of Soochow University · NCT06497452
This study is testing if adding glofitamab to standard treatments can help adults in China with relapsed or hard-to-treat B-cell non-Hodgkin lymphoma feel better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The First Affiliated Hospital of Soochow University (other) |
| Drugs / interventions | glofitamab |
| Locations | 1 site (Suzhou, Jiangsu) |
| Trial ID | NCT06497452 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the efficacy and safety of glofitamab in combination with salvage therapy in a real-world setting among Chinese adults diagnosed with relapsed or refractory B-cell non-Hodgkin lymphoma. Participants will receive glofitamab as part of their treatment regimen, and the study will monitor outcomes related to their response to therapy. The observational nature of the study allows for the collection of data from routine clinical practice rather than a controlled environment.
Who should consider this trial
Good fit: Ideal candidates for this study are Chinese adults who have been diagnosed with relapsed or refractory B-cell non-Hodgkin lymphoma and are set to receive glofitamab.
Not a fit: Patients currently participating in other interventional clinical trials or deemed unsuitable by the investigator will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new effective treatment option for patients with difficult-to-treat B-cell non-Hodgkin lymphoma.
How similar studies have performed: While this specific approach is being evaluated in a real-world setting, similar studies have shown promise in assessing the efficacy of glofitamab in treating B-cell non-Hodgkin lymphoma.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Be diagnosed as B-NHL * Relapse or refractory to previous treatment * Participants who will be treated with glofitamab Exclusion Criteria: * Participant who currently participates in or with plan to participate in any interventional clinical trial * Any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.
Where this trial is running
Suzhou, Jiangsu
- The First Affiliated Hospital of Soochow University — Suzhou, Jiangsu, China (RECRUITING)
Study contacts
- Study coordinator: Haiwen Huang
- Email: huanghaiwen@suda.edu.cn
- Phone: 0512-80668050
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: B-cell Non-Hodgkin Lymphoma